Core Viewpoint - Baiyang Pharmaceutical (301015.SZ) has signed a distribution agreement with Guangzhou Junxin Pharmaceutical Co., Ltd. to exclusively promote, sell, and distribute the product Anbomei in specific markets within the agreed period [1] Group 1 - The agreement was signed on November 4, 2025, and outlines the rights and obligations of both parties [1] - Junxin is a subsidiary of Jetabellin (Asia Pacific) Limited, which operates sales in China through Junxin [1] - Baiyang Pharmaceutical has been collaborating with Jetabellin on the retail market for Anbomei since March 2021, and this new agreement expands their cooperation into broader retail and hospital markets, excluding specific lists provided by Junxin [1]